How many investments has OUP (Osage University Partners) made?

OUP (Osage University Partners) has 138 tracked investments, 30 of which have exited, including 3 dated in the last 24 months.

What stage does OUP (Osage University Partners) invest at?

OUP (Osage University Partners) invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is OUP (Osage University Partners)'s typical check size?

OUP (Osage University Partners) typically writes checks of $1M – $20M.

What sectors does OUP (Osage University Partners) focus on?

OUP (Osage University Partners) focuses on AI & Machine Learning, Biotech, Cleantech, Climate Tech, Cloud Computing, Cybersecurity, Deep Tech, Digital Health, Energy, Enterprise Software, Hardware, Healthtech, Medical Devices, New Materials, Quantum Computing, SaaS, Sector Agnostic, Semiconductors.

Where is OUP (Osage University Partners) located?

OUP (Osage University Partners) is headquartered in Bala Cynwyd, US.

Does OUP (Osage University Partners) lead rounds?

Yes, OUP (Osage University Partners) leads investment rounds.

Who does OUP (Osage University Partners) co-invest with?

OUP (Osage University Partners) most often shares deals with ARCH Venture Partners, GV (Google Ventures), Canaan Partners, among 327 tracked co-investors.

OUP (Osage University Partners)

Venture capital

Bala Cynwyd · Pre-Seed–Late Stage · 21 people tracked

Also known as Osage University Partners · OUP MANAGEMENT CO., LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into OUP (Osage University Partners)

Paths you didn't know you had: your email and LinkedIn already hold routes to the OUP (Osage University Partners) team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

OUP backs startups commercializing transformational deep-technology innovations that emerge from or are inspired by breakthrough scientific research. For over 15 years the firm has focused specifically on science-driven companies, drawing on a team of former scientists, consultants, and operators to help founders convert laboratory discoveries into market-ready products. It emphasizes expertise in university tech transfer ecosystems, working closely with TTOs, principal investigators, and students. As a long-term partner, OUP reserves meaningful capital for follow-on rounds and connects portfolio companies to a network of Fortune 500 leaders, strategic partners, founders, and other investors to support commercial growth.

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Pre-Seed–Late Stage

Check

$1M – $20M

Bala Cynwyd, Pennsylvania, US

Leads rounds

Leads

Instruments

Equity

Founded

2009

Last 12 months

1 investment

AUM

$800M

VC funds

Tracked investments

138

Unicorns

IPOs

Acquisitions

Team · 21 people

from the firm's website & public directories

Anna Turetsky· General Partner, PxB Fund· New York, New York, United Statesin

Anna Turetsky joined OUP in 2025 as General Partner of the $50M PxB Fund (Penn-BioNTech Innovative Therapeutics Seed Fund), focusing exclusively on life science companies emerging from University of Pennsylvania technologies. She previously launched and led the venture investing arm of the Mark Foundation for Cancer Research and began her career at Lightstone Ventures. She holds a Ph.D. in Biophysics from Harvard University and a B.A. in Biochemistry from the University of Pennsylvania.

Louis Berneman· Founding Partner· Naples, Florida, United Statesin

Louis Berneman heads Texelerate, LLC, a technology transfer consultancy specializing in startup investment, royalty monetization, and licensing transactions. He is founding partner emeritus of Osage University Partners and fund advisor emeritus to HealthCare Royalty Partners, with prior experience as managing director of the Center for Technology Transfer at the University of Pennsylvania. Over 30 years, he has worked in intellectual property licensing, business development, and entrepreneurial activities, and holds certifications as a Licensing Professional and Registered Technology Transfer Professional.

lberneman@oup.vc

Manny Stockman· Managing Partner· Greater Philadelphiain 𝕏

Manny Stockman is Managing Partner at Osage University Partners, a venture capital fund that invests in technology spinouts from partner universities across the US, Canada, Israel, and the UK. His investment portfolio spans deep technology across computing, sensing, materials, and software sectors, including companies such as SiFive, IonQ, NuMat, Censys, and Delfi Diagnostics.

mstockman@oup.vc

Matt Cohen· Managing Partner· Philadelphia, Pennsylvaniain 𝕏

Matt Cohen is Managing Partner at Osage University Partners, a venture capital firm investing in innovative technologies derived from university research. He previously worked as a management consultant on projects spanning growth strategy, portfolio prioritization, commercialization planning, and commercial due diligence across multiple industries. Cohen has extensive knowledge of vaccine, immunologic, biologic, and small molecule therapeutic approaches in U.S., European, Brazilian, and Asian markets, with investments in numerous biotechnology companies including PMV Pharmaceuticals, Kura Oncology, Biohaven Pharma, Beam Therapeutics, and Sana Biotechnology.

mcohen@oup.vc

Robert Adelson· Managing Partner· Merion, PAin

Robert Adelson runs complementary early-stage B2B SaaS and university-spinout funds, combining corporate law and 1990s buyout experience with long-tenure VC insight and a 50-year university-ecosystem focus.

radelson@osagepartners.com

Kirsten Leute· Partner· Los Altos, California, United Statesin 𝕏

Kirsten Leute has 19 years of experience in technology transfer, including roles at Stanford University and the German Cancer Research Center. Before joining OUP, she served as Associate Director at Stanford's Office of Technology Licensing, where she managed portfolios of inventions across many technology areas with a concentration in biotechnology. She is a former two-time board member of the Association of University Technology Managers and co-founded Equalize Startups, a nonprofit supporting women-led startups.

kleute@oup.vc

Mitra Miri· Partner· United Statesin 𝕏

Principal on OUP's life science team, focused on working with scientific and academic founders in the early stage.

mmiri@oup.vc

Allen Chen· Principal· New York, New York, United Statesin

Allen Chen is a Principal on the technology investment team at Osage University Partners, focusing on software, hardware, and computing. Before OUP, he spent four years at BMW i Ventures leading early-stage investments in robotics, critical minerals, cybersecurity, and enterprise software, and held operating roles at Uber and Lilium. He started his career as a strategy consultant at L.E.K. Consulting and holds a BBA from Emory University.

achen@oup.vc

Ajay Rayasam· Principal· San Francisco Bay Areain 𝕏

Ajay Rayasam joined Osage University Partners in 2021 as an associate on the technology investment team, focusing on software, computing, and hardware opportunities. He previously served as Chief of Staff and Product Manager at enterprise software startup Kubisys, and holds an M.S. from MIT and a B.Sc. from Babson College.

arayasam@oup.vc

Beth Grafstrom· Senior Vice Presidentin

Beth Grafstrom joined OUP in 2015. She previously worked at New Mountain Capital as a Private Equity Fund Accountant and later as the Business Development Company Controller, and before that was a Senior Associate in the Banking Capital Markets Assurance practice at PricewaterhouseCoopers. She holds a B.S. from the University of Scranton and is a New York State CPA.

bgrafstrom@oup.vc

Britt Kennett· Senior Executive Assistant· King of Prussia, PAin

Britt Kennett joined OUP as an Executive Assistant in 2015. Before that, she spent about ten years at D.A. Kreuter Associates, an executive search firm focused on financial services, where she served as Director of Client Services. She holds a BA in Psychology from Villanova University.

bkennett@oup.vc

Brittany de Kouchkovsky· Director, University Relations· San Diego, California, United Statesin

Brittany de Kouchkovsky is Director at Osage University Partners, where she works on startup sourcing and development. She has experience in life sciences venture investment, biotech venture creation, academic technology sourcing, and early-stage therapeutic operations and development.

bdekouchkovsky@oup.vc

Chris Nawalinski· Fund Accountant· Morrisville, Pennsylvania, United Statesin

Claudia Dunnous· Chief Financial Officer· Philadelphia, Pennsylvania, United Statesin

Claudia Dunnous joined Osage Partners in 2006 and is a CPA with over 25 years of experience across private equity, retail, and manufacturing. She previously served as Vice President of Finance and Operations at Hamburger Color Company, a privately held manufacturer, where she led its sale to a strategic buyer, and earlier provided accounting and business advisory services at Grant Thornton and Laventhol and Horwath. She holds a BA in Economics from Brandeis University and an MBA in Accounting from Drexel University.

cdunnous@osagepartners.com

Kayti Mangels· Executive Assistant and Program Coordinator· Philadelphia, PAin

Kayti Mangels joined OUP as an Administrative Assistant in 2021. Previously, she supported the Office Manager and COO at Golden Eagle Coin, and before that spent three years as an elementary school teacher in North Philadelphia. She holds a B.S. in Early Childhood Education with a minor in Special Education from Chestnut Hill College.

kmangels@oup.vc

Kumar Patel· Fund Controller· Greater Philadelphiain

Kumar Patel joined Osage University Partners in 2019. He previously worked as a Senior Fund Accountant at The Rock Creek Group and as a Supervisor at SEI Investments. He holds a B.A. in Accounting from Arcadia University and is a CPA.

kpatel@oup.vc

Sami Nabil· Analyst· Philadelphia, Pennsylvania, United States

Sami Nabil is an Analyst at Osage University Partners, which he joined after nearly two years as a co-op with the firm. He works across the investment lifecycle, including fund operations, deal sourcing, and diligence. Before OUP, he was an Industrial Engineering Co-op at The Estée Lauder Companies, and he graduated magna cum laude from Drexel University with a B.S. in Physics, where he conducted neutrino physics research; he is also a deferred MBA admit at Columbia Business School.

Justin Robeny· Associate· New York, New York, United Statesin

Justin Robeny joined Osage University Partners in 2024 as an associate on the life sciences team, focusing on biotech investments across therapeutic areas. He previously was an analyst at Octagon Capital Advisors covering oncology and immunology healthcare investments, and worked in clinical operations at Axsome Therapeutics. He holds an M.Sc. in clinical research from the Icahn School of Medicine at Mount Sinai and a B.A. in human health from Emory University.

jrobeny@oup.vc

Marc A. Singer· Managing Partner· Greater Philadelphiain

Managing Partner focused on technology investments at OUP, contributing perspectives on early- and late-stage VC selection.

msinger@oup.vc

Nabil Ullah· Associate· Greater Philadelphiain

Author of the OUP insights article on startup equity allocation for academic spinouts.

nullah@oup.vc

William Harrington· Managing Partner· Philadelphia, Pennsylvaniain

Bill Harrington joined OUP in 2012 and, as a Managing Partner, oversees the firm's life science investment activities and shares day-to-day execution responsibilities. He previously spent over a decade as a General Partner at Three Arch Partners investing in therapeutics, medical devices, and healthcare services, and earlier practiced as an interventional radiologist. He holds a BS from Tufts, an MD from Harvard Medical School, an MBA from UC Berkeley, and the CFA designation.

bharrington@oup.vc

What they invest in

from 101 of 138 portfolio companies

Biotech ×59Healthtech ×33AI & Machine Learning ×24Medical Devices ×19Deep Tech ×18Hardware ×11Digital Health ×9Enterprise Software ×9

HQs:United States×98Israel×2

Who they back

founder profiles across 77 portfolio companies

35%

solo founders

27 of 77 mapped founding teams

28%

repeat founders

of 61 founders with career history

~2.5 yrs

old at investment

median across 28 dated deals

Founding team size:solo founder×272 founders×223 founders×134+ founders×15

Where their founders studiedfrom 59 founders with education data

University of California, Berkeley ×11Harvard University ×5The Johns Hopkins University School of Medicine ×5Massachusetts Institute of Technology ×4Stanford University ×4UC San Diego ×3Caltech ×2Case Western Reserve University School of Medicine ×2

What their founders studiedfrom 64 founders with field-of-study data

Engineering ×24Life Sciences ×15Computer Science ×14Chemistry ×10Medicine ×7Physics ×7Business & Management ×4Finance & Accounting ×2

Where their founders worked beforefrom 61 founders with career history

Carnegie Mellon University ×3Harvard Medical School ×3Juniper Networks ×3University of Washington ×3Apple ×2Broad Institute of MIT and Harvard ×2Columbia University in the City of New York ×2Defense Advanced Research Projects Agency (DARPA) ×2

45 founders hold a PhD · 6 hold an MBA (of 64 with degree data)

Investments · 138 tracked

founders shown can be your intro path

By year:2026 · 1 2025 · 2 2024 · 3 2023 · 2 2022 · 4 2021 · 1 2020 · 3 2019 · 2 2018 · 3 2017 · 3 2016 · 3 2015 · 345 dated

A Place for Momfiscloudservices.comNASDAQ: GDRXacquired by Exit Blackstone · Jul 2025 · $2.6B

A Place for Mom is a U.S. and Canadian senior care referral marketplace connecting families with senior living and home care providers.

Vernon Hills, US

Douglas Hirsch(Director)Trevor Bezdek(Co-Chairman & Director)Jonathan Stevens(Executive Officer)Thomas Richards(Executive Officer, Director)Christine Leahy(Executive Officer)Dennis Berger(Executive Officer)

Co-investorsBain Capital Double Impact Fund LP Bain Capital Life Sciences Bain Capital Tech Opportunities Bessemer Venture Partners Blue Sea Capital Bosch Ventures +38 more

Ambiqambiq.com in 𝕏NYSE: AMBQ

Ambiq develops ultra-low-power semiconductor solutions and edge AI platforms for IoT and healthcare applications.

AI & Machine LearningIoTSemiconductorsAustin, US

Scott Hanson(Founder)in Dennis Sylvester(Founder)inFumihide Esaka(CEO)in Scott Goodwin(Executive Officer)inJoseph A. Tautges(Director)Paul Rolls(Executive Officer)

Co-investorsCisco Investments Conductive Ventures Kleiner Perkins Matter Venture Partners Mercury Fund Michigan Capital Network +5 more

Beam Therapeuticsbeamtx.com in 𝕏NASDAQ: BEAMNov 2018

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.

BiotechDeep TechMedical DevicesCambridge, US

David R. Liu(Founder)inJ. Keith Joung(Founder)inFeng Zhang(Founder)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)

Co-investorsARCH Venture Partners Dreamers VC Eight Roads Ventures F-Prime Capital Foresite Capital GV (Google Ventures)+2 more

Context Therapeuticscontexttherapeutics.com in 𝕏NASDAQ: CNTXMay 2024

Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors.

BiotechHealthtechPhiladelphia, US

Martin Lehr(Founder)in Jennifer Minai-Azary(Executive Officer)inAlex Levit(Executive Officer)Linda Beth West(Director)Richard Jay Berman(Director)Philip Kantoff(Director)in

Co-investorsNextech Invest Torrey Pines Investment

Evolv Technologies inNASDAQ: EVLV

Evolv Technologies provides artificial intelligence-powered screening systems for weapons detection at facilities including schools, hospitals, stadiums, and workplaces, delivered through a subscription model that combines proprietary sensor hardware, cloud-based software, and analytics dashboards with ongoing support services.

Waltham, US

Anil Chitkara(Executive Officer)Michael Ellenbogen(Executive Officer, Director)Kevin O'Brien(Executive Officer)John Kedzierski(Chief Executive Officer, President, and Director)inGeorge C. Kutsor(Chief Financial Officer)Robert Marshall(Chief Revenue Officer)in

Co-investorsDCVC (Data Collective)Lux Capital

Gevogevo.comNASDAQ: GEVOJun 2014

Gevo produces low-carbon drop-in fuels and chemicals — including motor fuels, sustainable aviation fuel (SAF), and renewable materials — using CO2 as a renewable carbon source.

CleantechClimate TechEnergyEnglewood, US

Christopher Ryan(Executive Officer)Mike Willis(Executive Officer)Greg Roda(Executive Officer)Patrick Gruber(Executive Officer, Director)inBrett Lund(Executive Officer)Paul D. Bloom(Chief Executive Officer and Director)in

Co-investorsGiant Leap

Guardant Healthguardanthealth.com in 𝕏NASDAQ: GH

Guardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease.

BiotechDigital HealthHealthtechMedical DevicesRedwood City, US

AmirAli Talasaz(Founder)in Helmy Eltoukhy(Founder)in Michael Wiley(Executive Officer)inMichael Bell(Chief Financial Officer)Darya Chudova(Chief Technology Officer)inCraig Eagle(Chief Medical Officer)in

Co-investors8VC AUTHENTIC VENTURES CLI Ventures Cota Capital Felicis Ventures Khosla Ventures +10 more

Kura Oncologykuraoncology.com inNASDAQ: KURA

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

PINGDA REN(Executive Officer)inYI LIU(Executive Officer)in Troy Wilson(Founder)inTroy Wilson, Ph.D., J.D.(Co-founder; President, Chief Executive Officer and Chairman of the Board)Kevan M. Shokat, Ph.D.(Founding team member)HEIDI HENSON(Executive Officer)in

Co-investorsARCH Venture Partners Avoro Capital Advisors EcoR1 Capital Foresite Capital Nextech Invest

Mirna Therapeuticsblogmedicina.com 𝕏OTC: SYBXSeries C · Oct 2012 · $35M

A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.

BiotechMedia & EntertainmentAustin, US

Matthew Winkler(Director)Sinil Kim(Executive Officer)in Paul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)

BoardMichael Powell(Director)

Co-investorsNew Enterprise Associates (NEA)Pfizer Venture Investments Correlation Ventures OrbiMed Pfizer Ventures Sofinnova Ventures

Precision BioSciencesprecisionbiosciences.com in 𝕏NASDAQ: DTIL

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

BiotechDeep TechHealthtechDurham, US

MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)in Derek Jantz(Co-founder)inTODD MELBY(Executive Officer)in Michael Amoroso(President, Chief Executive Officer)in

Board ROBERT ADELMAN(Director)

Co-investorsage1 Agent Capital Aliment Capital Brace Pharma F-Prime Capital OCV Partners +6 more

Prime Medicineprimemedicine.com in 𝕏NASDAQ: PRME

Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.

BiotechDeep TechHealthtechMedical Devices

Andrew Anzalone(Founder)in David Liu(Co-founder)in Allan Reine(Chief Executive Officer)in Mohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in

Co-investorsARCH Venture Partners GV (Google Ventures)Newpath Partners F-Prime Capital Samsara BioCapital Arrive +1 more

Q32 Bioq32bio.com in 𝕏NASDAQ: QTTB

Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.

BiotechHealthtech

Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)in David Appugliese(Senior Vice President, Head of People)in

Co-investorsAtlas Venture OrbiMed Agent Capital CU Healthcare Innovation Fund Sanofi Ventures 5AM Ventures +2 more

Sera Prognosticsseraprognostics.com in 𝕏NASDAQ: SERA

Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.

BiotechDigital HealthFemTechHealthtechSalt Lake City, US

Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)inGregory C. Critchfield(Executive Officer, Director)in Andrew A. Sauter(Executive Officer)inZhenya Lindgardt(President and Chief Executive Officer)in

BoardMansoor Mirza(Director)

Co-investorsaMoon Excelestar Ventures Intermountain Health UpStart Ventures Vivo Capital Catalyst Health Ventures +1 more

Spero Therapeuticssperotherapeutics.com inNASDAQ: SPRO

Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.

BiotechCambridge, US

Ankit Mahadevia(Executive Officer, Director)in Stephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in

Board Jean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)

Co-investorsGV (Google Ventures)HEALTHCARE ROYALTY PARTNERS MRL Ventures Fund RA Capital Alphabet Atlas Venture +1 more

Veradermicsveradermics.com inNYSE: MANE

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.

BiotechHealthtechWest Hartford, US

Reid Waldman(Chief Executive Officer and Board Member)in Tim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)

Co-investorsLongitude Capital Connecticut Innovations LifeSci Venture Partners SR One Capital Management abrdn plc Invus

Vor Biopharmavorbio.comNASDAQ: VORJun 2020

Vor Biopharma is a biopharmaceutical company.

BiotechCambridge, US

Nathan Jorgensen(Executive Officer)Amy Mendel(Executive Officer)Robert Ang(Executive Officer, Director)Jean-Paul Kress(President, Chief Executive Officer and Chairman of the Board)in

Board Kush Parmar(Director)inJoshua Resnick(Director)

Co-investors5AM Ventures RA Capital PureTech Health

Eridueridu.ai in 𝕏Mar 2026✓ verified

Eridu develops networking infrastructure optimized for artificial intelligence workloads.

AI & Machine LearningCloud ComputingDeep TechHardwareSaratoga, US

Drew Perkins(Founder)in Brian Kinard(Executive Officer)in

BoardJagdeep Singh(Director)Dipender Saluja(Director)Wen Hsieh(Director)inChristian Gallagher(Director)

Co-investorsBosch Ventures Catapult Ventures Matter Venture Partners Socratic Partners TDK Ventures Zelda Ventures +13 more

Aerie Pharmaceuticalsaeriepharma.com inSep 2014

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.

BiotechHealthtechMedical DevicesBedminster, US

CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in

Co-investorsAlta Partners Avoro Capital Advisors Foresite Capital Sofinnova Ventures

Agita Labsagitalabs.comDec 2020

Agita Labs develops hardware security and computer architecture technology focused on secure computation and side-channel resistance techniques.

CybersecurityDeep TechHardwareAnn Arbor, US

Valeria Bertacco(Co-founder)Todd Austin(Co-founder)Amy Wirth(Chief Financial Officer)Lip-Bu Tan(Director)

Algorithmiaalgorithmia.com inAcquired

Algorithmia offers an enterprise AI platform for developing, deploying, and governing machine learning models and AI applications, with tooling tailored to roles across data science, engineering, DevOps, and IT teams.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareSeattle, US

Kenneth F. Daniel(Executive Officer, Director)Diego M. Oppenheimer(Executive Officer, Director)inDiego Oppenheimer(Founder)Kenny Daniel(Founder)

Board Timothy Porter(Director)in Anna Patterson(Director)in

Co-investorsGradient Ventures In-Q-Tel Madrona Venture Group Deep Fork Capital Norwest Venture Partners Work-Bench

Alphina Therapeuticsalphinatx.com in

Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University.

BiotechNew Haven, US

Barbara Fox(Executive Officer, Director)inNicholas J Galli(Executive Officer, Director)Stanley Choy(Executive Officer)in Ranjit Bindra(Director)in

Board Colleen Cuffaro(Director)inMatthew Cohen(Director)in

Co-investorsCanaan Partners Connecticut Innovations HighCape Capital

Antiva Biosciencesantivabio.com in

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

Karl Y. Hostetler(Executive Officer, Director)in Gail Maderis(Director)in Kristine Ball(President & CEO)in Elaine Chien(Executive Officer)inSarah Walter(Executive Officer)in Raju Gadiraju(Executive Officer)in

Co-investorsAdjuvant Capital Avestria Ventures Brace Pharma Canaan Partners GV (Google Ventures)HBM Healthcare Investments +6 more

Aptinyxaptinyx.com

BiotechEvanston, US

Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)

BoardLiam Ratcliffe(Director)Terry P. Gould(Director)

Co-investorsBain Capital Life Sciences Frazier Life Sciences Latterell Venture Partners Longitude Capital Agent Capital Bain Capital +3 more

Arrakis Therapeuticsarrakistx.com in 𝕏

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)in David Neafus(Executive Officer)inRussell C. Petter(Executive Officer)

Board Colleen Cuffaro(Director)in Alan E. Walts(Director)in

Co-investorsCanaan Partners Pfizer Ventures Advent Life Sciences HBM Healthcare Investments HBM Partners Nextech Invest +2 more

Arsenal Biosciencesarsenalbio.com

Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)Alexander Marson(Founder)Kole Roybal(Founder)

Co-investorsARCH Venture Partners Hitachi Ventures Kleiner Perkins Luma Group SoftBank Vision Fund Westlake Village BioPartners +4 more

Asset Watchassetwatch.com in 𝕏Series A · Jun 2022 · $9M

AssetWatch provides cloud-based asset monitoring software and sensor technology to help manufacturing and industrial facilities prevent unplanned equipment downtime.

Advanced ManufacturingEnterprise SoftwareIoTSaaSWesterville, US

William Zell(Executive Officer, Director)William Ruff(Executive Officer)inRobert Lee(Director)inTad Dritz(VP of Development)in Jeff Haskett(COO)inBrian Graham(Executive Officer, Director)in

Co-investorsCerity Partners Ventures G2 Venture Partners Harmonic Growth Partners JobsOhio Ventures Monte Carlo Capital Triangle Peak Partners +4 more

Biohaven Pharmaceuticalsbiohavenpharma.com in 𝕏

Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.

BiotechHealthtech

Vlad Coric(Chairman & Chief Executive Officer)in

Co-investorsAisling Capital APERTURE Venture Partners Connecticut Innovations HBM Healthcare Investments OrbiMed

Brimstonebrimstone.com inMar 2022

Brimstone develops co-production processes to manufacture cement, steel, aluminum, and other critical minerals from a single feedstock in an integrated facility.

Advanced ManufacturingCircular EconomyCleantechConstruction TechNew MaterialsOakland, US

Cody Finke(Founder)inHugo Leandri(Founder)in

Co-investorsAccelr8 Breakthrough Energy Ventures Collaborative Fund Creative Destruction Lab (CDL)DCVC (Data Collective)Fifth Wall +7 more

Cell Design Labscelldesignlabs.com

BiotechLafayette, US

Peter Emtage(Executive Officer)inGreg Giotta(Executive Officer)Brian Atwood(Executive Officer, Director, Promoter)

BoardFred Cohen(Executive Officer, Director, Promoter)Brook Byers(Director)inArie Belldegrun(Director)

Co-investorsKleiner Perkins Mission Bay Capital Mission Biocapital

Censyscensys.com in 𝕏

Censys operates an Internet-wide scanning map that provides real-time data on Internet infrastructure, delivered through a platform for exploring exposure, dependencies, and attacker infrastructure.

CybersecurityData & InfrastructureSaaSAnn Arbor, US

J. Alex Halderman(Founder)Zakir Durumeric(Founder)inBrad Brooks(Former CEO)David Corcoran(Founder)Lorne Groe(Former Interim CEO; later CFO/COO)Sarah Ashburn(Chief Revenue Officer)

Co-investorsAscension Ventures Decibel Partners Greylock Partners GV (Google Ventures)Hamilton Lane Intel Capital +3 more

Chroma Medicinechromamedicine.com

nChroma Bio is a genetic medicines company developing in vivo therapies that pair genetic cargoes with targeted delivery technologies.

BiotechLongevityBoston, US

Angelo Lombardo(Founder)David R. Liu(Founder)J. Keith Joung(Founder)Jonathan S. Weissman(Founder)Luigi Naldini(Founder)Luke Gilbert(Founder)

Co-investorsWellington Management Atlas Venture Casdin Capital GV (Google Ventures)Newpath Partners

Clarifaiclarifai.com in 𝕏

Clarifai developed AI inference technology and compute orchestration software for running and optimizing machine learning models at scale.

AI & Machine LearningCloud ComputingData & InfrastructureNew York, US

Matthew Zeiler(Founder)in

Board Albert Wenger(Director)in

Co-investorsBright Pixel Capital Corazon Capital GV (Google Ventures)Lux Capital Menlo Ventures New Enterprise Associates (NEA)+10 more

Cleave Biosciencescleavetherapeutics.com

BiotechBurlingame, US

Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)inTimothy Smith(Executive Officer)

Board Alfred Scheidegger(Director)in Peter Thompson(Director)in Carol Gallagher(Director)in

Co-investorsAstellas Venture Management LLC New Enterprise Associates (NEA)Nextech Invest 5AM Ventures Clarus Ventures OrbiMed +1 more

Clinipaceclinipace.comSeries C · Sep 2011 · $15M

Caidya is a contract research organization (CRO) that provides scientific, medical, and operational support for clinical development and cross-border clinical trials.

BiotechDigital HealthHealthtechMorrisville, US

Mark Ubert(Executive Officer)Jesse Watson(Director)Brian Carney(Director)Jeff L. Williams(Executive Officer, Director)Melissa Daniels(Director)Christopher K. Porter(Executive Officer)

Co-investorsCreathor Ventures Hatteras Venture Partners

Corelightcorelight.com in 𝕏

Corelight provides network detection and response (NDR) software that uses agentic triage to automatically consolidate security alerts into entity-centric cases with evidence-backed investigation summaries.

AI & Machine LearningCybersecurityEnterprise Software

Seth Hall(Founder)inGreg Bell (CEO)(Founder)Robin Sommer(Founder)Vern Paxson(Founder)

Co-investorsAccel Cisco Investments Delta-v Capital Energy Impact Partners Flucas Ventures General Catalyst +7 more

CounterflowAIcounterflow.aiJan 2018

Crozet, US

Randy Caldejon(Chairman, Chief Executive Officer and President)Erik Breuhaus(Chief Financial Officer)Peter Shaw(Vice President)in

BoardMatthew Swartz(Director)

Co-investorsTFX Capital Tiburon

Cyteir Therapeuticscyteir.com in 𝕏

Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.

BiotechHealthtechCambridge, US

Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)in Donald Corcoran(Executive Officer, Director)in Markus Renschler(Director)in

BoardTimothy Romberger(Director)Barry Mills(Director)

Co-investorsDroia Ventures Lightstone Ventures Shah Family Office Ally Bridge Group De Novo Ventures Janus Henderson Investors +3 more

Delfi Diagnosticsdelfidiagnostics.com in

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US

Victor Velculescu(Founder)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)in Susan Tousi(Chief Executive Officer)in

Co-investorsAV8 Ventures Foresite Capital Illumina Ventures Initiate Venture Partners Menlo Ventures Merck Global Health Innovation Fund +7 more

Dracen Pharmaceuticalsdracenpharma.com

Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.

BiotechHealthtechBaltimore, US

Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)

Board Jonathan Leff(Director)Robert Jackson(Director)

Co-investorsBiotech Investments S.R.O i&i Biotech Fund Deerfield Management Company Sofinnova Ventures

Effector Therapeuticseffector.comSeries A · May 2013 · $45M

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.

BiotechSolana Beach, US

Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)in

BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)

Co-investorsAstellas Venture Management LLC Mission Bay Capital Mission Biocapital Pfizer Venture Investments US Venture Partners Sofinnova Ventures

eGenesisegenesis.com

Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.

BiotechBrookline, US

Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)

Board George M. Church(Director)

Co-investorsAlta Partners ARCH Venture Partners Catalio Capital Management, LP HBM Healthcare Investments HBM Partners Khosla Ventures +12 more

Elementaryelementary-data.com in 𝕏

Elementary builds data observability tools that monitor data quality and reliability for modern data teams.

AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise SoftwareTel Aviv-Yafo, IL

Maayan Salom(Founder)in Or Avidov(Founder)in

Co-investorsCowboy Ventures Modern Technical Y Combinator Accuro Trustees Tetration Labs Threshold Ventures +1 more

Elementary Roboticselementaryrobotics.com in 𝕏

Elementary Robotics develops machine vision inspection systems for industrial quality control and defect detection.

Advanced ManufacturingAI & Machine LearningRobotics

Arye Barnehama(Founder)

Co-investorsIdealab Riot Ventures Thundermark Capital Fathom Capital Fika Ventures Rewired +4 more

EnaChipenachip.com

EnaChip develops integrated magnetic structures — thin, small inductors fabricated with semiconductor-compatible electroplating — for point-of-load power delivery in AI infrastructure, advanced packaging, chiplets, and edge systems.

Deep TechHardwareSemiconductorsWilmington, US

Trifon M Liakopoulos(Executive Officer, Director, Promoter)Mark Allen(Co-Founder & CTO)Mark Popovich(CEO)inMichael Cassidy(Director)Michael Poisel(Director)

Board MICHAEL BURYCHKA(Director)in

Co-investorsAnzu Partners Boston Seed Capital

Escient Pharmaceuticalsescientpharma.com

Company developing molecules targeting a novel class of receptors for neuro-immuno-inflammatory diseases; acquired by Incyte in May 2024.

BiotechSan Diego, US

Alain Baron(Founder)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Founder)

Board Andrew Schwab(Director)in

Co-investors5AM Ventures Avego BioScience Capital New Enterprise Associates (NEA)Sanofi Ventures The Column Group Abingworth +2 more

Everactiveeveractive.comSeries A · Nov 2014 · $5M

Everactive develops ultra-low power, self-powered systems-on-chip (SoCs) for Ambient IoT devices that sense, process, and wirelessly transmit data using harvested environmental energy instead of batteries.

HardwareIoTSemiconductorsSan Jose, US

Benton Calhoun(CEO and Co-Founder)inDavid Wentzloff(CTO and Co-Founder)inBrendan R Richardson(Executive Officer, Director)

BoardGeorge Kastendike(Director)Greg Papadopoulos(Director)inJack Busch(Director)

Co-investorsAsahi Kasei Corporate Venture Capital Blue Bear Capital Partners In-Q-Tel New Enterprise Associates (NEA)ABB Technology Ventures Fluke Venture Partners +1 more

Faraday Pharmaceuticalsfaradaypharma.comDefunct

Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.

BiotechSeattle, US

Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)

Board Paulina Hill(Director)in Steven Gillis(Executive Officer, Director, Promoter)in

Co-investorsARCH Venture Partners Polaris Partners

Fortis Therapeuticsfortistx.com

Fortis Therapeutics develops therapeutic treatments based on technology licensed from UCSF, with a focus on oncology and other disease areas.

BiotechHealthtechMedical DevicesSan Diego, US

Marc Nasoff(Chief Scientific Officer)

Board Jay B. Lichter(Ph.D.)in

Co-investorsVivo Capital Lilly Asia Ventures Avalon BioVentures

Glyphic Biotechnologiesglyphic.bio in 𝕏Feb 2024

Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.

BiotechDeep TechBerkeley, US

Daniel Estandian(Founder)inEd Boyden(Founder)Josh Yang(Founder)inJoshua Yang(Founder)

Board Craig Asher(Director)in Jimmy Yun(Director)in

Co-investorsArtis Ventures Black Flag Civilization Ventures Management, Llc FoundersX Ventures Harpoon Ventures In-Q-Tel +9 more

Hack The Boxhackthebox.com in 𝕏

Hack The Box provides hands-on training and simulation platforms for cybersecurity blue teams, including labs, courses, and incident response exercises designed to develop skills in SOC operations, digital forensics, and threat hunting.

AI & Machine LearningCybersecurityDeveloper ToolsEdTechEnterprise Software

Co-investorsBrighteye Ventures Marathon Venture Capital Paladin Capital Group

Homology Medicineshomologymedicines.com inJul 2017

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)

Co-investors5AM Ventures ARCH Venture Partners Alexandria Deerfield Management Company Fidelity Investments HBM Healthcare Investments +5 more

Hyalexhyalex.com in 𝕏Series A · Sep 2024 · $16M

HYALEX Orthopaedics develops a synthetic cartilage platform for joint repair in orthopaedic surgery.

HealthtechMedical DevicesLexington, US

Carl Vause(Executive Officer, Director)in Mira Sahney(Executive Officer, Director)inDavid Myung(Director)

BoardMichael Hawkins(Director)Wende Hutton(Director)in William Harrington(Director)in

Co-investorsCanaan Partners Treo Ventures, Llc Johnson & Johnson Innovation – JJDC

Immune Designimmunedesign.com 𝕏Acquired

Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.

BiotechHealthtechMedical DevicesSeattle, US

David Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in

Co-investorsAisling Capital Atlas Venture HM Venture Partners Sanderling Ventures Sanofi Ventures SPRINGROCK VENTURES +4 more

Immventiontheraimmventionthera.com inDec 2022

Immvention Therapeutics develops first-in-class BACH1 inhibitors intended as an oral therapy for patients with sickle cell disease and other conditions.

BiotechDigital HealthChapel Hill, US

Jenny Ting(Director and Co-founder)Matthew Cohen(Director)Lev Osherovich(Director)Mark Vellaca(Director)Anil Goyal(CEO and Director)

BoardBenjamin Scruggs(Director)

Co-investorsDelin Ventures Hatteras Venture Partners

Infinioinfinio.com

IgniteTech is an AI-first enterprise software company that acquires, revitalizes, and supports a portfolio of mission-critical software products for organizations worldwide.

AI & Machine LearningEnterprise SoftwareSaaS

Eric Vaughan(CEO)

Infinite Uptimeinfinite-uptime.com in 𝕏Dec 2016

Infinite Uptime builds PlantOS, a prescriptive AI platform for heavy manufacturing that reads mechanical and process-induced fault signatures to tell plant operators which equipment fault to fix, why, and by when.

Advanced ManufacturingAI & Machine LearningIoTMenlo Park, US

Raunak Bhinge(Founder & MD)inJean-David Margulici(Executive Officer, Director)Yung Chih Chen(Founder)Karthikeyan Natarajan(Chief Executive Officer)

Co-investorsAvataar Venture Partners Dorm Room GiTV, Inc.Mayfield Fund Pear VC TDK Ventures +3 more

Interius BioTherapeuticsinteriusbio.com

BiotechPhiladelphia, US

Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in

BoardTomas Kiselak(Director)

Co-investorsAgent Capital DC Investment Partners Longwood Fund Pfizer Venture Investments Quan Capital Bain Capital Life Sciences +3 more

Kate Therapeuticskatetherapeutics.com in 𝕏

BiotechSan Diego, US

Kevin Forrest, Ph.D.(Executive Officer, Director)

BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)

Co-investorsWestlake Village BioPartners Kleiner Perkins Versant Ventures

KenScikensci.comAcquired

Vertically-integrated machine learning platform for healthcare powering transition to value-based care with predictive analytics.

Co-investorsMindset Venture Polaris Partners

Kymetakymetacorp.com inSeries C · Jun 2013 · $50M

Kymeta develops flat-panel satellite antennas and connectivity terminals, including its u5 and u8 product lines, that switch between LEO and GEO networks for mobile land and maritime use.

Defense TechHardwareSpace TechRedmond, US

Marc Stolzman(Executive Officer)inBill Marks(Executive Officer)Keith Cochran(Executive Officer)in Manny Mora(CEO)inAnne(Chief Financial Officer)inRyan(Chief Scientist)in

Co-investorsLux Capital Manta Ray Ventures Tectonic Ventures Intellectual Ventures

Lastlinelastline.comAcquired

American network security company offering malware sandboxing and AI-based network detection and response; acquired by VMware in 2020.

Redwood City, US

Giovanni Vigna(Executive Officer, Director)Engin Kirda(Executive Officer)Christopher Kruegel(Executive Officer)Jens Andreassen(Executive Officer, Director)

Board John Walecka(Director)inAndreas Von Blottnitz(Director)

Co-investorsPresidio Ventures Redpoint Ventures Ballistic Ventures Headline NTT Finance Thomvest Ventures

Luxteraluxtera.comOct 2013

Global leader in silicon photonics, first to achieve direct 'fiber to the chip' integration on CMOS.

Carlsbad, US

Eli Yablonovitch(Director)Greg Young(Executive Officer, Director)inTom Foody(Executive Officer)Axel Scherer(Founder)

BoardAndy Rappaport(Director)Rohini Chakravarthy(Director)in

Co-investorsATEL Ventures August Capital Cisco Investments TEL Venture Capital, Inc.New Enterprise Associates (NEA)

MC10mc10inc.com in 𝕏Series A · Jul 2010 · $6Macquired by Medidata

MC10 developed conformal BioStamp wearable sensors and clinical analytics for physiological data capture in clinical research.

BiotechDigital HealthHealthtechMedical DevicesLexington, US

John Rogers(Director)David Icke(Executive Officer, Director)Alice Sansone(Executive Officer)Steven N. Tannenbaum(Executive Officer)Scott D. Pomerantz(Executive Officer, Director)

Board Marc Singer(Director)in

Co-investorsBraemar Energy Ventures Mitsui Global Investment Windham Capital Partners Aberdare Ventures North Bridge Venture Partners & Growth Equity

Menlo Securitymenlosecurity.com in 𝕏Seed · Jan 2014

Menlo Security provides a browser security platform that protects both human users and AI agents through a hybrid architecture combining local security controls with cloud-based threat protection.

AI & Machine LearningCybersecurityEnterprise SoftwareMountain View, US

Amir Ben-Efraim(Founder)inPoornima DeBolle(Founder)in

Co-investorsBaruch Future Ventures Engineering Capital General Catalyst Junipero Vista Equity Partners WillowTree Ventures +3 more

Metalenzmetalenz.com in 𝕏

Metalenz develops metasurface optics technology for optical sensing in consumer and industrial devices.

Deep TechHardwareSemiconductorsStoneham, US

Federico Capasso(Co-founder)in Rob Devlin(Co-Founder and CEO)in

Board Xuhui Shao(Director)in

Co-investorsBantam Group Braemar Energy Ventures Foothill Ventures Global Brain Intel Capital M Ventures +5 more

Mobiamedicalmobia.com in 𝕏Jun 2022 · $73M

Mobia Medical (formerly MicroTransponder) develops Vivistim Paired VNS Therapy, an FDA-approved vagus nerve stimulation treatment for chronic ischemic stroke survivors with moderate to severe upper extremity impairment.

HealthtechMedical Devices

Jordan Curnes(Co-Founder)in

Co-investorsGreen Park & Golf Ventures Longitude Capital US Venture Partners

Neuros Medicalneurosmedical.comSeries A · Aug 2017 · $20M

Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.

BiotechHealthtechMedical DevicesAliso Viejo, US

David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)in

Board Joyce Erony(Director)in William Harrington(Director)in

Co-investorsAmzak Health APERTURE Venture Partners CWRU Technology Ventures iSelect Fund JobsOhio Ventures Jumpstart Ventures +5 more

Nocion Therapeuticsnociontx.com in 𝕏

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.

BiotechHealthtechMedical DevicesWatertown, US

MATTHEW FRANKEL(Executive Officer)inPETER COUROSSI(Executive Officer)RICHARD BATYCKY(President and Chief Executive Officer)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)inCHRISTOPHER SILBER(Executive Officer)in

Co-investorsCanaan Partners F-Prime Capital Lumira Ventures Mission Biocapital Monograph Capital Partners

Normunitynormunity.com in 𝕏

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.

BiotechHealthtech

Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)in William LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)

Co-investorsSanofi Ventures Taiho Ventures, LLC Pfizer Ventures Samsara BioCapital Canaan Partners Connecticut Innovations +6 more

Opsysopsys-tech.com in

Opsys develops solid-state scanning LiDAR sensors with no moving parts, using VCSEL and SPAD chip technology for autonomous driving and industrial applications.

AI & Machine LearningDeep TechHardwareRoboticsIsrael, IL

Guy Gertel(Founder)Rafi Harel(Founder)

Co-investors83North Saban Ventures TransLink Capital

Overland Aioverland.ai

Overland AI develops ground autonomy solutions for military vehicles and land operations, enabling autonomous mobility without human operators.

AI & Machine LearningDefense TechRoboticsSeattle, US

Byron Boots(Founder)inStephanie Bonk(Founder)inGreg Okopal(Founder)inJonathan Fink(Executive Officer)

BoardChristopher Morales(Director)

Co-investors8VC Alumni Ventures Ascend Venture Capital Cubit Capital Overmatch Pioneer Square Labs +7 more

Picwellpicwell.com in 𝕏Acquired

Picwell operates ALEX, a benefits decision-support platform that combines plan recommendations, enrollment, benefits administration, and year-round guidance for employees.

HR TechInsurTechSaaSPhiladelphia, US

Thomas Baker(Executive Officer, Director)Jonathan Thompson Kolstad(Executive Officer, Director)Robert James Town(Executive Officer, Director)Jay Silverstein(Executive Officer, Director)inAnirudh Vemprala(Executive Officer, Director)

BoardKevin Hill(Director)

Co-investorsBlue Venture Funds MassMutual Ventures SeaX Ventures BlueCross BlueShield Venture Partners

Pionyr Immunotherapeuticspionyrtx.com in

HealthtechSan Francisco, US

Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)inLeon Chen, Ph.D.(Director)Carol Gallagher(Director)inJoshua Resnick, M.D.(Director)

BoardMichael Powell(Director)

Co-investorsMission Bay Capital Mission Biocapital New Enterprise Associates (NEA)Sofinnova Ventures OrbiMed Sofinnova Venture Partners

PMV Pharmapmvpharma.comFeb 2017

PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function.

BiotechHealthtechCranbury, US

David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Director)

Board Peter Thompson(Director)inSteve Winick(Director)Arnold Oronsky(Director)

Co-investorsAvoro Capital Advisors Nextech Invest RA Capital Viking Global Wellington Management OrbiMed

Precedeprecede.bio in 𝕏

Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.

AI & Machine LearningBiotechDigital HealthBoston, US

Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)in Sylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)inToni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)

Co-investors5AM Ventures Illumina Ventures Alexandria Lilly Asia Ventures S28 Capital

Quantum Circuitsquantumcircuits.com inAcquired

Quantum Circuits develops superconducting quantum computers using dual-rail qubits with built-in error detection, designed to accelerate the path to fault-tolerant quantum computing.

Advanced ManufacturingDeep TechHardwareQuantum ComputingMadison, US

Rob Schoelkopf(Sterling Professor, Founder)inLuigi Frunzio(Founder)Ray Smets inMichel Devoret(Founder)Robert Schoelkopf(Founder)

Co-investorsARCH Venture Partners Canaan Partners Connecticut Innovations F-Prime Capital Fitz Gate Ventures In-Q-Tel +2 more

Quintessentquintessent.comSeed · Oct 2023 · $12M

Quintessent develops optical connectivity solutions to address chip-to-chip communication bottlenecks in large-scale computing and AI systems.

AI & Machine LearningCloud ComputingDeep TechHardwareSemiconductorsSanta Barbara, US

Alan Liu(CEO, Co-Founder & Board Member)inBrian Koch(VP of Engineering & Co-Founder)inJohn Bowers(Chairman of the Board & Co-Founder)

Co-investorsEntrada Ventures Foothill Ventures M Ventures Sierra Ventures

Receptosreceptos.com inFeb 2012Acquired

San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.

BiotechSan Diego, US

Marcus Boehm(Executive Officer)inRobert Peach(Executive Officer)inRaymond Stevens(Director)inFaheem Hasnain(Executive Officer, Director)inJames Schmidt(Executive Officer)inChrysa Mineo(Executive Officer)in

Co-investorsARCH Venture Partners Ridgeback Capital Venrock Lilly Ventures

ReCode Therapeuticsrecodetx.com in 𝕏

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Co-investorsAju IB Investment EcoR1 Capital Evolution VC Partners MPM BioImpact OrbiMed Pfizer Venture Investments +6 more

Redonaredonatx.com in

Redona Therapeutics is a drug discovery company co-founded by Harvard Medical School investigators focused on novel areas of biology.

AI & Machine LearningBiotechBoston, US

George Daley(Co-founder)Richard Gregory(Co-founder)Frank Slack(Co-founder)Piotr Sliz(Co-founder)inKazumi Shiosaki(President & CEO)in

Co-investorsAstellas Venture Management LLC Sofinnova Partners

Ribon Therapeuticsribontx.com inDec 2015 · $10M

BiotechLexington, US

Victoria M. Richon(Executive Officer, Director)in

BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)

Co-investorsAvego BioScience Capital Peregrine Ventures AbbVie Deerfield Management Company JJDC Novartis Venture Fund +3 more

Sana Biotechnologysana.com in

Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.

BiotechHealthtechMedical DevicesSeattle, US

Richard Mulligan(Director)inHans Bishop(Founder)Steve Harr(Founder)James J. MacDonald(Executive Officer)Nathan Hardy(Executive Officer)

Board Geoffrey von Maltzahn(Director)in

Co-investorsAmerican Family Ventures ARCH Venture Partners Catalytic Impact Foundation F-Prime Capital Flagship Pioneering GV (Google Ventures)+8 more

Satsuma Pharmaceuticalssatsumarx.com

Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101).

BiotechHealthtechMedical DevicesSouth San Francisco, US

John Kollins(Executive Officer, Director)Tadayoshi Iwashima(Executive Officer)Thomas B. King(President and Board Director)inRob Janosky(Chief Commercial Officer)Tom O'Neil(Chief Financial Officer)inDavid Prichard(Chief Operating Officer)

Co-investorsVivo Capital Wellington Management Lumira Ventures RA Capital Red Tree Venture SBI Investment

Seismosseismos.com in 𝕏

Seismos provides an AI intelligence layer that converts acoustic signals and sensor measurements into real-time completion decisions for oil and gas well operators.

AI & Machine LearningDeep TechEnergyAustin, US

Panagiotis Adamopoulos(Executive Officer, Director)Panos Adamopoulos(Founder)inJeffrey Harris(Director)John Bain(Director)

Board Noah Doyle(Director)in

Co-investorsEdison Partners Javelin Venture Partners

SiFivesifive.com in 𝕏

SiFive develops processor IP based on the open-standard RISC-V instruction set architecture, offering customizable and scalable chip designs.

Deep TechHardwareSemiconductorsSan Francisco, US

Yunsup Lee(Founder)inKrste Asanovic(Director)inAndrew Waterman(Founder)in Stefan A Dyckerhoff(Executive Officer, Director)in Naveed Sherwani(Executive Officer)in Patrick Little(CEO)in

Co-investorsBerkeley SkyDeck Fund Coatue Management Ibex Investors Intel Capital Prosperity7 Ventures Qualcomm Ventures +9 more

Skytreeskytree.net

The site is a Dutch-language affiliate portal that ranks and reviews online casinos targeting players in the Netherlands, offering casino comparisons, bonus guides, and gambling information.

ConsumerMedia & Entertainment

Co-investorsJavelin Venture Partners US Venture Partners

Snowcap Computesnowcapcompute.com inJun 2025

Snowcap Compute develops superconducting computing platforms using Josephson Junctions to replace semiconductor transistors, delivering orders-of-magnitude greater energy efficiency for AI and high-performance computing workloads.

AI & Machine LearningDeep TechSemiconductorsSan Francisco, US

Anna Herr(Founder)inQuentin Herr(Founder)inMichael Shamus Lafferty(Executive Officer, Director)Michael Lafferty(Founder)

Board Pat Gelsinger(Director)inRichard Hyman(Director)

Co-investorsPlayground Global ATEL Ventures Cambium Capital Page One Ventures

Sonoma Biotherapeuticssonomabio.com in 𝕏Jul 2021

Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Jeffrey Bluestone(Founder)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)

Co-investors8VC ARCH Venture Partners Frazier Life Sciences GV (Google Ventures)JDRF T1D Fund LAV +6 more

Streetlight Datastreetlightdata.com in 𝕏Series B · Mar 2016 · $10M

StreetLight provides big data analytics for transportation planning and infrastructure investment decisions.

Climate TechData & InfrastructureGovTechLogistics & Supply ChainMobility & TransportationSan Francisco, US

Paul Friedman(Founder, Chief Technology Officer)in Laura Schewel(Executive Officer, Director, Promoter)in

BoardBill Perry(Director)Scott Pinizzotto(Director)Marc Singer(Director)inDarlene Mann(Director)

Co-investorsACTIVATE CAPITAL PARTNERS

Tessera Labstesseralabs.ai in 𝕏

Tessera provides a multi-agent AI platform for enterprise system modernization, automating processes across ERP, CRM, HCM, and finance systems with governed execution.

AI & Machine LearningEnterprise SoftwareSaaS

Kabir Nagrecha(Chief Executive Officer)inMing Chang(Chief Operating Officer)in Anirudh Sriram(Chief Technology Officer)in Prakash Gupta(Chief Revenue Officer)in

Co-investorsAndreessen Horowitz Clear Ventures Foundation Capital Myriad Venture Partners

Trellis Airtrellisair.com in 𝕏Mar 2025

Trellis Air develops technology aimed at drying air using less energy.

CleantechClimate TechEnergySomerville, US

Russ Wilcox(Executive Officer, Director)

BoardCraig Shapiro(Director)

Co-investorsWorkshop Venture Partners Founder Collective

TruLite Healthtrulitehealth.com inSeries A · Aug 2023 · $7M

Trulite Health builds Truity, a health optimization platform that delivers clinical, social, and behavioral decision support and patient-facing nudges to providers and care teams at the point of care.

Digital HealthHealthtechSaaSTempe, US

Alan C. Roga(Executive Officer, Director)inJohn Barravecchia(Executive Officer)in Shaung Liu(Executive Officer)in

BoardCaleb DesRosiers(Director)

Co-investorsOsage Venture Partners Service Provider Capital Inflect Health

Urjaneturjanet.com 𝕏

Arcadia (urjanet.com) offers a platform that unifies utility bill and interval data, tariff and energy rate calculations, and solar and storage analysis into energy data and analytics.

CleantechClimate TechData & InfrastructureEnergyAtlanta, US

SANJOY MALIK(Executive Officer, Director)in

Board PETER KIGHT(Director)in STEVE FREDRICK(Director)inSIG MOSLEY(Director)DAVID RATCLIFFE(Director)

Co-investorsCorrelation Ventures Grotech Ventures Oak HC/FT Commerce Ventures GRA Venture Imlay Investments

Vanqua Biovanquabio.com in 𝕏

Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.

BiotechDeep TechHealthtechLongevityChicago, US

Rand Sutherland(Director)in Jim Sullivan(CEO)in Kevin Hunt(CSO)in

Board Jonathan Silverstein(Director)inBernard Davitian(Director)Uya Chuluunbaatar(Director)

Co-investorsAvoro Capital Advisors OrbiMed Pontifax Venture Capital Casdin Capital Omega Funds

Verdoxverdox.com in

Verdox develops an electrochemical carbon capture system that uses electrical energy alone to capture and release CO₂ from both industrial point sources and ambient air.

CleantechClimate TechDeep Tech

Alan Hatton(Founder)Brian Baynes(Founder)Sahag Voskian(Founder)

Co-investorsAzolla Ventures Breakthrough Energy Ventures Lowercarbon Capital Prime Impact Fund

Verve Motionvervemotion.com in 𝕏

Verve Motion develops the SafeLift exosuit, a wearable device designed to reduce workplace injuries and increase productivity for physically demanding jobs.

Future of WorkHardwareLogistics & Supply ChainRoboticsCambridge, US

Ignacio Galiana(Founder)in

Co-investors515 Ventures Construct Capital Cybernetix Ventures Founder Collective Pillar VC Safar Partners

Virtue Aivirtueai.com in 𝕏

Virtue AI offers an enterprise AI security platform that applies real-time guardrails, red-teaming, and compliance controls to AI models and agentic systems.

AI & Machine LearningCybersecurityEnterprise SoftwareSan Francisco, US

Sanmi Koyejo(Founder)inBo Li(Founder)in Dawn Song(Founder)inCarlos Guestrin(Founder)in

Co-investorsLightspeed Venture Partners Walden Catalyst

Voxel8voxel8.comJul 2015Acquired

Company producing world's first multi-material 3D printer capable of printing functional features with variable material properties.

Somerville, US

Jennifer A. Lewis(Executive Officer, Director)

Board Jiong Ma(Director)Clinton Bybee(Director)in

Co-investorsBraemar Energy Ventures In-Q-Tel ARCH Venture Partners

Xscape Photonicsxscapephotonics.com in

Xscape Photonics develops custom silicon photonics solutions aimed at solving bandwidth bottlenecks in AI compute clusters.

AI & Machine LearningDeep TechSemiconductorsFort Lee, US

Alexander Gaeta(Executive Officer, Director)inVivek Raghunathan(Executive Officer, Director)inYoshitomo Okawachi(Executive Officer)Alexander Kash(Executive Officer, Director)

BoardJames Scapa(Director)

Co-investorsCisco Investments LifeX Ventures Addition AltaIR Capital Fathom Fathom Fund +2 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Aerovate TherapeuticsAGTCArtizan BiosciencesAtsena TherapeuticsAvid RadiopharmaceuticalsBioAgeBlade Therapeutics Body LabsCapella BioscienceCardioxyl PharmaceuticalsCartesiaCleave TherapeuticsCoho TherapeuticsDICE TherapeuticsE-scape BioEinblickEmbodiedExostellarGraphite Bio, Inc.HiddenWeightsIconic Therapeutics Kolltan Pharmaceuticals Landos BiopharmaLunaDNAMediSix TherapeuticsMillendo TherapeuticsModis TherapeuticsNeurosNidobioNuMatOtonomyPalladio Biosciences Paracosm Perceptive AutomataResolv TechnologySelecta BiosciencesSynthorx Tangent Medical TechnologiesVector Space Systems

Exits · 30

17 IPOs · 13 acquisitions · showing 21

A Place for MomNASDAQ: GDRXAmbiqNYSE: AMBQBeam TherapeuticsNASDAQ: BEAMContext TherapeuticsNASDAQ: CNTXEvolv TechnologiesNASDAQ: EVLVGevoNASDAQ: GEVOGuardant HealthNASDAQ: GHKura OncologyNASDAQ: KURAMirna TherapeuticsOTC: SYBXPrecision BioSciencesNASDAQ: DTILPrime MedicineNASDAQ: PRMEQ32 BioNASDAQ: QTTBSera PrognosticsNASDAQ: SERASpero TherapeuticsNASDAQ: SPROVeradermicsNYSE: MANEVor BiopharmaNASDAQ: VORAerovate Therapeuticsacq. by Jade BiosciencesMC10acq. by MedidataMillendo Therapeuticsacq. by Tempest TherapeuticsModis Therapeuticsacq. by ZogenixSynthorxacq. by Sanofi

Portfolio news

latest coverage across their companies

Veradermics to Present at Upcoming September 2026 Investor Conferences - BioSpace

Veradermics · biospace.com · Sep 4, 2026

Prime Medicine to Participate in Upcoming September 2026 Investor Conferences - BioSpace

Prime Medicine · biospace.com · Sep 3, 2026

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace

Precision BioSciences · biospace.com · Aug 6, 2026

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics · globenewswire.com · Aug 4, 2026

Censys Delivers Record First-Half 2026 Growth as AI-Driven Demand for Internet Intelligence Accelerates

Censys · PR Newswire · Jul 22, 2026

Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant deal

Q32 Bio · stocktitan.net · Jul 15, 2026

Spero Therapeutics licenses SP001, raises $105M | SPRO 8-K Filing

Spero Therapeutics · stocktitan.net · Jul 14, 2026

Arrakis Therapeutics Announces CEO Transition with Mark DeLong Appointed as New CEO - BioSpace

Arrakis Therapeutics · biospace.com · Jun 25, 2026

Frequently asked questions

How many investments has OUP (Osage University Partners) made?: OUP (Osage University Partners) has 138 tracked investments, 30 of which have exited, including 3 dated in the last 24 months.
What stage does OUP (Osage University Partners) invest at?: OUP (Osage University Partners) invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is OUP (Osage University Partners)'s typical check size?: OUP (Osage University Partners) typically writes checks of $1M – $20M.
What sectors does OUP (Osage University Partners) focus on?: OUP (Osage University Partners) focuses on AI & Machine Learning, Biotech, Cleantech, Climate Tech, Cloud Computing, Cybersecurity, Deep Tech, Digital Health, Energy, Enterprise Software, Hardware, Healthtech, Medical Devices, New Materials, Quantum Computing, SaaS, Sector Agnostic, Semiconductors.
Where is OUP (Osage University Partners) located?: OUP (Osage University Partners) is headquartered in Bala Cynwyd, US.
Does OUP (Osage University Partners) lead rounds?: Yes, OUP (Osage University Partners) leads investment rounds.
Who does OUP (Osage University Partners) co-invest with?: OUP (Osage University Partners) most often shares deals with ARCH Venture Partners, GV (Google Ventures), Canaan Partners, among 327 tracked co-investors.

Media · Podcasts & interviews

featuring the team

University Spinouts and Deep Tech Investing | Marc Singer | Osage University Partners (OUP)

Deep Tech Leaders · Marc Singer

Ventures #15 w/ Matt Cohen - Managing Partner @ Osage University Partners (OUP) | BIOS

BIOS · Matt Cohen

Founder's Equity: Formation, Dilution, Industry Averages - Manny Stockman, Osage University Partners

UCLA TDG · Manny Stockman

Marc Singer, John Lee (Osage University Partners)

Marc Singer · vimeo.com

Advisory Boards in Academic Innovation: Three University Models

Osage University Partners

SBIR/STTR Reauthorization: Tips and Tricks for Navigating New Funding Opportunities

Osage University Partners

Images

Co-investors · 47

OrbiMed

OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 10

Mirna Therapeutics Q32 Bio Biohaven Pharmaceuticals Cleave Biosciences Delfi Diagnostics Pionyr Immunotherapeutics PMV Pharma ReCode Therapeutics Synthorx Vanqua Bio

$1M – $75M

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 8

Mirna Therapeutics Clarifai Cleave Biosciences Escient Pharmaceuticals Everactive Luxtera Metalenz Pionyr Immunotherapeutics

$200K – $40M

Canaan Partners

Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.

Both backed · 7

Alphina Therapeutics Antiva Biosciences Arrakis Therapeutics Hyalex Nocion Therapeutics Normunity Quantum Circuits

$500K – $20M

5AM Ventures

5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.

Both backed · 7

Q32 Bio Vor Biopharma Cleave Biosciences Escient Pharmaceuticals Homology Medicines PrecedeCleave Therapeutics

$100K – $4M

US Venture Partners

US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.

Both backed · 5

Cleave Biosciences Effector Therapeutics Mobiamedical Neuros Medical Skytree

$500K – $10M

Nextech Invest

Nextech Invest is a Zurich-based investor backing emerging biotechnology companies worldwide, focused on advancing precision medicine and transformative cancer therapies.

Both backed · 5

Context Therapeutics Kura Oncology Arrakis Therapeutics Cleave Biosciences PMV Pharma

$648K – $3.2M

Lux Capital

Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.

Both backed · 4

Evolv Technologies Clarifai eGenesis Kymeta

$100K – $100M

Deerfield Management Company

Deerfield Management is a healthcare-focused investment firm that supports companies across the healthcare ecosystem through flexible funding, market intelligence, and philanthropic initiatives.

Both backed · 4

Blade Therapeutics Dracen Pharmaceuticals Homology Medicines Ribon Therapeutics

MPM BioImpact

MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.

Both backed · 4

Antiva Biosciences Blade Therapeutics Iconic Therapeutics ReCode Therapeutics

$1M – $15M

The Column Group

The Column Group (TCG) is a venture capital ecosystem focused on the life sciences, funding scientific innovation and building biotech companies from formation through exit.

Both backed · 4

Escient Pharmaceuticals Immune Design Ribon TherapeuticsCleave Therapeutics

$30M

Agent Capital

Agent Capital is a healthcare venture capital firm that makes direct equity investments in novel, differentiated therapeutics and treatments addressing unmet patient needs, from preclinical through commercial stages.

Both backed · 4

Precision BioSciences Q32 Bio Aptinyx Interius BioTherapeutics

Bessemer Venture Partners

Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.

Both backed · 3

A Place for Mom Guardant HealthNidobio

$50K – $100M

▶35 more co-investors

Versant Ventures Hatteras Venture Partners Braemar Energy Ventures General Catalyst Khosla Ventures Javelin Venture Partners Breakthrough Energy Ventures Deep Fork Capital Domain Associates Omega Funds RiverVest Venture Partners APERTURE Venture Partners Madrona Venture Group Sierra Ventures American Express Ventures (Amex)G2 Venture Partners EQT Life Sciences MassMutual Ventures JAZZ Venture Partners Engineering Capital SR One Capital Management Johnson & Johnson Innovation – JJDC Aberdare Ventures Signet Healthcare Partners Plug and Play Ventures Company Capital Gutbrain Ventures Calibrate Ventures Venture Guides Management, L.P.Pivotal Life Sciences Newfund Capital Amara VC Medical Excellence Capital Chrysalix BrightCap Investment Advisor AD

Firms observed investing alongside OUP (Osage University Partners), from public investor directories. Shared companies are the overlap with OUP (Osage University Partners)'s recorded portfolio.

Similar investors

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Khosla Ventures

Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.

$100K – $20M

Bosch Ventures

Robert Bosch Venture Capital GmbH (Bosch Ventures) is the corporate venture capital arm of Robert Bosch, headquartered in Stuttgart, Germany, with offices across Europe, the US, Israel, and China.

$1.6M

Alumni Ventures

Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.

$100K – $10M

Everywhere Ventures

Everywhere Ventures is an early-stage venture firm that writes pre-seed checks and is backed by a community of founder and operator LPs.

$250K

Featured in lists

Investors & VC Firms in North America Seed Investors & VC Firms Investors & VC Firms in United States Series A Investors & VC Firms Seed Investors & VC Firms in North America Pre-Seed Investors & VC Firms Seed Investors & VC Firms in United States Investors & VC Firms in Global AI & Machine Learning Investors & VC Firms Growth Investors & VC Firms SaaS Investors & VC Firms Series A Investors & VC Firms in North America